مواقع التدريسيينجامعة الكوفة
Akeel Abdulkadhum Jassim Abo Alard
Lecturer

Akeel Abdulkadhum Jassim Abo Alard

0Publications
0Lectures
0Interests

About

I gained my BSc from the Faculty of Pharmacy at the Kufa University in 2005. .This was followed by MSc (2012) in Pharmaceutical Chemistry from the College of Pharmacy at the University of Baghdad. I was promoted to lecturer in 2022. I have got a PhD in Pharmacy in 2021 under the supervision of Prof Peter Fischer in the School of Pharmacy at the University of Nottingham in UK.. I work in the area of Medicinal and Pharmaceutical Chemistry.

Research Interests

1

Publications

8
2026

In silico, design, synthesis and evaluation of new naphthyridine-dione analogues as potential candidates for carbonic anhydrase inhibitors

AuthorsAkeel Abo Alard, Atheer Mohammed Jasim , Ammar Azzam
JournalKufa Journal of Pharmaceutical Sciences
Date2026-01-31
Abstract

Hypoxia in many kinds of solid tumours represent the main factor to induce Carbonic anhydrase IX (CAIX) and thus supports tumour pH homeostasis under low-oxygen condition. In mouse models, pharmacological CAIX inhibition has been shown to delay tumour growth, reduce metastatic spread, and restrain cancer stem cell expansion. Accordingly, targeting carbonic anhydrase overexpression—especially CAIX—represents a promising anticancer approach. Based on this premise, a new series of naphthyridinedione derivatives (5a to 5c) was designed, synthesised, and evaluated in cell lines (HCT116 and MCF-7), with acetazolamide (ACZ) used as a control compound. To prioritise the most promising candidates, molecular docking (Schrödinger Maestro 2021-1 and PyMOL) was performed prior to synthesis to select compounds with the highest predicted binding. Antiproliferative effects were then measured using an MTT assay in both cell models. Relative to acetazolamide, compound 5c demonstrated substantially greater antiproliferative potency in HCT116 (IC₅₀ = 1.08 μM) and MCF-7 cells (IC₅₀ = 1.49 μM) compared with acetazolamide (IC₅₀ = 1.79 μM and 2.55 μM, respectively). In contrast, compounds 5a and 5b exhibited cytotoxicity broadly comparable to acetazolamide. Collectively, these findings suggest that naphthyridinedione derivatives (5a–c) provide a useful starting scaffold for further anticancer drug development. Docking analyses further indicated that 5c achieved more favourable S-scores than acetazolamide, consistent with stronger predicted binding to the CAIX active site. The methoxy substituent and the naphthyridinedione core may contribute to increased conformational flexibility and improved receptor interactions. Overall, these naphthyridinedione derivatives (5a–c) show notable CAIX-related inhibitory potential alongside measurable cytotoxicity, supporting continued evaluation as anticancer lead compounds.

2026

Design, Synthesis, Cytotoxic Evaluation and Docking Study of Dihydrobenzofuran Derivatives as a Potential Candidate for Cancer Therapy

AuthorsAkeel Abo Alard
JournalInternational Research Journal of Pharmacy and Medical Sciences
Date2026-04-01
Abstract

Abstract—Overexpression of CAIX for many research represent as an attractive therapeutic target in oncology. Therefore, a number of novel dihydrobenzofuran derivatives (5a–5d) was designed, synthesised, and anticancer activity was investigated using both molecular docking simulations and cytotoxicity testing. The synthetic route applied some of key reagents such as sulfanilamide, thiourea and substituted dihydrobenzofuran. For computational docking analyses Schrodinger Maestro software release 2021-1 was used for this purpose. While, cell viability was evaluated via the MTT assay with using doxorubicin as a control compound. The newly prepared derivatives exhibited inhibitory effects on cancer cell survival. All compounds 5a-d achieved promising docking S-scores, suggesting stronger interactions within the receptor’s active site. Structural features such as chlorine, methyl, methoxy substituent and the dihydrobenzofuran moiety may enhance molecular flexibility and receptor engagement. In addition, structural incorporation of the thiazole moiety enhanced molecular flexibility and improved receptor-binding affinity. Also, formation of the metal complex further increased the compounds’ ability to suppress cellular proliferation. Regard to in vitro cytotoxicity study, among the tested compound 5b demonstrated moderate cytotoxic activity versus MCF-7 and HCT116 cell lines with the IC₅₀ values of 8.68 ± 0.87 and 7.24 ± 0.81 respectively. Compound 5d, also exhibited moderate activity versus the MCF-7 with an IC50 value of 9.24 ± 0.90 μM. However, this derivative exhibited reduced activity versus the HCT116 with an IC50 value of 15.33 ± 1.21 μM. Moreover, both 5a and 5c demonstrated a low level of cytotoxic activity effect on cell lines. These results suggest that the dihydrobenzofuran scaffold provides a promising foundation for further optimisation in anticancer drug development.

2025

Design, Synthesis and Cytotoxic Evaluation of New Quinolinedione Derivatives as Potential Candidates for the Treatment of Cancer

AuthorsAkeel Abo Alard
JournalKerbala Journal of Pharmaceutical Sciences
Date2025-12-31
Abstract

Background: Carbonic anhydrase IX (CAIX) affected by hypoxia and thus lead to upregulated in many types of tumors and thus helps in maintain tumor pH balance under these conditions. Pharmacologic inhibition of CAIX has been shown in mouse models to slow tumor growth, curb metastasis, and limit tumor stem cell expansion. Therefore, inhibiting the overexpression of CA, particularly CA IX, consider a promising anticancer therapy. Objective: The primary objective of this study was to design and synthesis of a set of new quinolinedione derivatives (5a-c), study antiproliferative activity by MTT assay against HCT116 cell lines and MCF-7 cell lines and molecular docking studies to prioritize candidates’ compounds with the highest predicted binding. Methods: The synthesis of new quinolinedione derivatives (5a-c) through derivatives bearing methylsulfonyl aniline scaffolds, characterized via TLC, melting point, and spectral data acquisition (HNMR, and CNMR), and cytotoxic evaluated for the synthesised derivatives using antiproliferative activity by MTT assay against HCT116 cell lines and MCF-7 cell lines. Results: Among the tested compounds, 7-methoxy-3,4-dihydroquinolin-2(1H)-one (compound 5c) exhibited markedly stronger antiproliferative activity in HCT116 cells (IC₅₀ = 0.98 μM) and MCF-7 cell lines (IC₅₀ = 1.39 μM) versus acetazolamide (IC₅₀ = 1.69 μM, IC₅₀ = 2.45 μM). While, both compounds 5a and 5b showed a close cytotoxic activity results to acetazolamide. These results position quinolinedione derivatives (5a-c) as a promising starting point for further development as an anticancer agent. Docking study indicated that 5c achieved good S-scores (-6.211) in compare with acetazolamide (-5.574), suggesting stronger affinity for the CA IX active site. The substituted methoxy group and quinolinedione scaffold appear to enhance flexibility and receptor interactions. Conclusion: Overall, the quinolinedione derivatives (5a-c) were effectively synthesized and exhibit meaningful CA IX inhibition and cytotoxic activity, supporting their further evaluation as potential anticancer leads.

2020

Design, Synthesis, Docking Study and Preliminary Pharmacological Assessment of New Norfloxacin Analogues Having Thiazole Nucleus

AuthorsNawal T. Ajjah, Nawal T. Ajjah, Noor H. Naser, Akeel A. Abo Alard, Muslim F. Diwan
JournalJ Biochem Tech
Date2020-08-14
Abstract

Abstract Bacterial resistance is the most dangerous and critical problem associated with the use of antibiotics, due to the uncontrolled and miss use of many types of them. Fluoroquinolones are a class of antibacterial agents that possess an anti-inflammatory effect in addition to their antibacterial effect, and they are resisted by many species of microorganisms through different mechanisms. It was found that increase bulkiness at C7 of fluoroquinolones moiety will reduce bacterial resistance by reducing the effect of the efflux pump, and it was also reported that this modification will improve anti-inflammatory activity. So, thiazole ring and a group of its derivatives (which possess antibacterial and anti-inflammatory activity) were incorporated into a secondary amine at the piperazine ring of norfloxacin. Using FT-IR spectroscopy, 1H-NMR spectral, and some physical-physiochemical properties, the synthesized compounds were confirmed and characterized for their chemical structures. In vivo, an acute anti-inflammatory effect of compounds, III and IVa-f, was estimated using the paw-edema model in rats. Norfloxacin 20mg/kg, and diclofenac sodium 3mg/kg were employed as reference drugs. All tested compounds exhibited significant (p<0.05) reduction in the paw edema when compared to the control group (propylene glycol (PG)). In in-vitro, the antibacterial effect of all synthesized compounds was evaluated via the use of the agar-well diffusion method (AWD). The antibacterial study was shown a topmost inhibition zone for the compound III against E. coli and the lowest inhibition zone for the compound IVd against Staphylococcus aureus. Docking studies showed the affinity of the synthesized compounds toward the topoisomerase enzyme.

2019

Design, synthesis, and pharmacological evaluation of new Lomefloxacin derivatives having oxadiazole nucleus

AuthorsSaeed, Ali R , Saeed, Ali R; Naser, Noor H; Alard, Akeel A Abo
JournalJournal of Pharmaceutical Sciences and Research;
Date2019-10-31
Abstract

Infectious diseases are accompanied by inflammation as a defense mechanism through the role of arachidonic acid cascade or cyclooxygenase enzyme. Many researches indicated that many types of fluoroquinolone antibiotics have anti-inflammatory effects in addition to their antibacterial activities. A group of oxadiazole derivatives were incorporated into C7 piperazine ring of lomefloxacin, a well-known antibacterial fluoroquinolone, in order to increase bulkiness at C7 leading to reduce bacterial resistance and improve anti-inflammatory activity. In the current work, an in vivo experiment via visualizing the acute anti-inflammatory activities of the final compounds (VIa-f) were tested encouraging inflammation using the egg-white induced-edema model (EWIE). The doses used were 10mg/kg and 3mg/kg for lomefloxacin and diclofenac, reference substances (RS), respectively. The results for this experiment showed significant (p<0.05) reductions in paw edema (PE) for all the compounds comparing that to the control group, propylene glycol (PG). However, compound VIb produced superior (p<0.05) anti-inflammatory activity compared to lomefloxacin. In vitro antibacterial evaluation using well disc diffusion method (WDDM) showed a comparable effect of the synthesized compound (SC) with lomefloxacin with the largest inhibition zone for compound VIa against Staphylococcus epidermis, and compound VIc produced superior antibacterial activity against Klebsiella pneumoniae when compared with lomefloxacin. Confirmations and characterization of the chemical structures related to these SCs were performed using 1 H-NMR spectroscopy, FTIR spectroscopy, and some physicochemical properties such as melting point and Rf value. Docking study of the final synthesized compounds gave evidence about the affinity of these compounds toward topoisomerase IV enzyme.

2018

Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B

AuthorsAlisa F Zyryanova, Félix Weis 2 3 4 5, Alexandre Faille 2 3 4, Akeel Abo Alard 6, Ana Crespillo-Casado 2, Yusuke Sekine 2, Heather P Harding 2, Felicity Allen 7, Leopold Parts 7, Christophe Fromont 6, Peter M Fischer 6, Alan J Warren 1 3 4 5, David Ron
JournalScience
Date2018-03-30
Abstract

The integrated stress response (ISR) is a conserved translational and transcriptional program affecting metabolism, memory, and immunity. The ISR is mediated by stress-induced phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) that attenuates the guanine nucleotide exchange factor eIF2B. A chemical inhibitor of the ISR, ISRIB, reverses the attenuation of eIF2B by phosphorylated eIF2α, protecting mice from neurodegeneration and traumatic brain injury. We describe a 4.1-angstrom-resolution cryo-electron microscopy structure of human eIF2B with an ISRIB molecule bound at the interface between the β and δ regulatory subunits. Mutagenesis of residues lining this pocket altered the hierarchical cellular response to ISRIB analogs in vivo and ISRIB binding in vitro. Our findings point to a site in eIF2B that can be exploited by ISRIB to regulate translation.

2015

DESIGN AND SYNTHESIS OF DICLOFENAC AND INDOMETHACIN – CONJUGATES WITH GEMCITABINE AS A POSSIBLE MUTUAL PRODRUGS

AuthorsDhurgham Q. Shaheed, Dhurgham Q. Shaheed, Ahmed Kareem Hussein Mubarak*, Akeel Abdulkadium Jassim Aboalard, Hayder Kadhium Abbas, Mohammed Dakhil ALRekabi,and Ahmed Hashim Husssein
JournalWorld Journal of PharmaceuticalResearchSJIF Impact F Research
Date2015-01-08
Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed classes of drugs and their long-term regimens have been greatly shortened due to their gastrointestinal side effects. COX-2 plays a pivotal role throughout oncogenesis and here we exploit the rationale to explore the use of NSAID (Diclofenac and indomethacin) in combination with current anticancer drug(Gemcitabine)for the prevention and/or treatment of cancer. The study describes design and synthesis of mutual pro-drug of NSAID and gemicitabine, which is designated to generate the complementary pharmacological action as a single chemical entity with improved drug targeting.The synthesis is conferred by FT-IR, CHNS and physiochemical properties. The newly designed mutual pro-drug is expected to reduce the side effects of NSAIDs on the gastrointestinal (GI) tract with improvement of the oral bioavailabilityand targetingof gemcitabine.

2012

Design, Synthesis and Preliminary Pharmacological Evaluationof New Non-Steroidal Anti-Inflammatory Agents Having a4-(Methylsulfonyl) Aniline Pharmacophore

AuthorsMonther Faisel Mahdi , Monther Faisel Mahdi 1, Mohamed Hassan Mohammed, Akeel Abdul Kadhum Jassim
JournalMolecules
Date2012-12-20
Abstract

A series of 4-(methylsulfonyl)aniline derivatives were synthesized in order to obtain new compounds as a potential anti-inflammatory agents with expected selectivity against COX-2 enzyme. In vivo acute anti-inflammatory activity of the final compounds 11–14 was evaluated in rat using an egg-white induced edema model of inflammation in a dose equivalent to 3 mg/Kg of diclofenac sodium. All tested compounds produced significant reduction of paw edema with respect to the effect of propylene glycol 50% v/v (control group). Moreover, the activity of compounds 11 and 14 was significantly higher than that of diclofenac sodium (at 3 mg/Kg) in the 120–300 minute time interval, while compound 12 expressed a comparable effect to that of diclofenac sodium in the 60–240 minute time interval time, and compound 13 showed a comparable effect to that of diclofenac sodium at all experimental times. The result of this study indicates that the incorporation of the 4-(methylsulfonyl)aniline pharamacophore into naproxen, indomethacine, diclofenac and mefanamic acid maintained their anti-inflammatory activity and may increase selectivity towards the COX-2 enzyme which will be confirmed in the future by assessing COX-2: COX-1 inhibitory ratios using a whole blood assay.

Lectures

11

What is a drug?

Pharmaceutical Chemistry

The adrenergic nervous system

Pharmaceutical Chemistry

Sympathomimetic Agents

Pharmaceutical Chemistry

Gastrointestinal agents: Acidifying agents

Inorganic Pharmaceutical Chemistry

Antacids

Inorganic Pharmaceutical Chemistry

Protective adsorbents

Inorganic Pharmaceutical Chemistry

CNS anti-depressants

Pharmaceutical Chemistry

Oxidation of aromatic ring

Metabolism of drugs

Oxidation of Olefine

Pharmaceutical Chemistry

METABOLIC CHANGES OF DRUGS AND RELATED ORGANIC COMPOUNDS

Pharmaceutical Chemistry

Part I- Drug Design Strategies

Pharmaceutical Chemistry

View details